Testosterone prescriptions in the United States have surged by approximately 50%, increasing from 7.3 million in 2019 to over 11 million in 2024. This rise is reshaping perceptions of aging, energy, and sexual health, but it has divided the medical community regarding the appropriateness of this treatment. The increase is particularly notable among men aged 35 to 54 and women aged 45 to 64, with many women seeking treatment for menopause-related symptoms. Factors contributing to this trend include unmet medical needs, commercial influences from new Low T clinics, and regulatory changes, such as the FDA's removal of the cardiovascular black box warning for testosterone in February 2025. However, concerns remain over the adequacy of bloodwork and monitoring prior to initiating testosterone replacement therapy (TRT). Doctors urge patients to ensure proper screening and to understand their hormonal health before beginning treatment. The article emphasizes that while testosterone therapy can address legitimate health issues, the rapid rise in prescriptions also raises questions about potential over-treatment and the need for careful clinical evaluation.